Karl Pfleger

Karl Pfleger, AI researcher turned longevity philanthropist and angel investor focused on rejuvenation biotech. He discusses why epigenetic reprogramming is powerful but incomplete. He outlines separable molecular pathologies and the need for combinatorial, repeatable rejuvenation therapies. He also explains why better diagnostics could unlock personalized aging interventions.

Karl Pfleger, an angel investor and creator of Aging Biotech Info, dives into the exciting world of rejuvenation biotechnology. He shares insights on the rapid advancements in the field, including breakthroughs in epigenetic reprogramming and stem cell therapies. Karl discusses the role of AI in streamlining clinical trials and the importance of investors in combating age-related diseases. He also explores the concept of longevity escape velocity and how individuals can contribute to this innovative sector.

Karl Pfleger, an aging biotechnology investor and creator of AgingBiotech.info, dives into the explosive growth of aging therapeutics. He distinguishes between interventions that slow aging and rejuvenation strategies that repair damage. Karl shares insights on promising therapies like senolytics and epigenetic reprogramming, while cautioning about the limitations of current aging clocks and popular weight-loss drugs. Highlighting recent FDA approvals and the necessity of a multi-target strategy for longevity, he also emphasizes the foundational role of diet, exercise, and sleep in maximizing healthspan.

Karl Pfleger, founder of AgingBiotech.info and a former Google researcher, dives deep into the rapidly evolving longevity biotech landscape. He discusses the lucrative opportunities in aging-related investments, highlighting how targeting aging could revolutionize health care. Pfleger stresses the importance of understanding mechanisms of action and shares his investment strategies. He also emphasizes the promise of senolytics, or senescent cell clearance, as a leading frontier. For aspiring investors, he recommends diving into conferences and varied resources for informed decisions.

Karl Pfleger, a Super Angel in longevity, shares his journey from AI to biotech investing. Topics include advancements in aging biology, challenges in biotech startups, advocacy space growth, building a biotech database, exploring aging drugs, and rejuvenation therapies for longevity.